You are here:

Candesartan cilexetil (Amias®)


Following a full submission

Candesartan (Amias) is accepted for use within NHS Scotland for the treatment of patients with heart failure and left ventricular systolic dysfunction (left ventricular ejection fraction = 40%) as add-on therapy to ACE inhibitors or in patients who are unable to tolerate ACE inhibitors. Treatment with candesartan reduces mortality and hospitalisation due to heart failure. Candesartan may be used as a second-line agent in patients with chronic heart failure and LVEF = 40% following treatment with an ACE inhibitor and diuretic and with or without a betablocker.

Drug Details

Drug Name: Candesartan cilexetil (Amias®)
SMC Drug ID: 161/05
Manufacturer: Takeda UK Ltd
Indication: Heart failure and left ventricular systolic dysfunction
BNF Category:
Sub Category: 2.5 Hypertension and heart failure
Submission Type: Full submission
Status: Accepted
Date Advice Published: 9 May 2005